SIRTUIN MODULATING COMPOUNDS
    2.
    发明申请
    SIRTUIN MODULATING COMPOUNDS 有权
    SIRTUIN调节化合物

    公开(公告)号:US20110015192A1

    公开(公告)日:2011-01-20

    申请号:US12891667

    申请日:2010-09-27

    CPC分类号: C07D513/04

    摘要: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

    摘要翻译: 本文提供了新的沉默调节蛋白的调节化合物及其使用方法。 沉默调节蛋白的调节化合物可用于增加细胞的寿命,以及治疗和/或预防各种各样的疾病和病症,包括例如与老化或紧张相关的疾病或病症,糖尿病,肥胖症,神经变性疾病, 心血管疾病,凝血障碍,炎症,癌症和/或潮红以及由线粒体活性增加所致的疾病或病症。 还提供了包含与另一种治疗剂组合的沉默调节蛋白的调节化合物的组合物。

    Sirtuin modulating compounds
    3.
    发明授权
    Sirtuin modulating compounds 有权
    沉默调节蛋白调节化合物

    公开(公告)号:US07829556B2

    公开(公告)日:2010-11-09

    申请号:US12214804

    申请日:2008-06-20

    IPC分类号: A61K31/535 C07D413/00

    CPC分类号: C07D513/04

    摘要: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

    摘要翻译: 本文提供了新的沉默调节蛋白的调节化合物及其使用方法。 沉默调节蛋白的调节化合物可用于增加细胞的寿命,以及治疗和/或预防各种各样的疾病和病症,包括例如与老化或紧张相关的疾病或病症,糖尿病,肥胖症,神经变性疾病, 心血管疾病,血液凝固障碍,炎症,癌症和/或潮红以及将受益于增加的线粒体活性的疾病或病症。 还提供了包含与另一种治疗剂组合的沉默调节蛋白的调节化合物的组合物。

    Sirtuin modulating compounds
    6.
    发明授权
    Sirtuin modulating compounds 有权
    沉默调节蛋白调节化合物

    公开(公告)号:US08247565B2

    公开(公告)日:2012-08-21

    申请号:US12891667

    申请日:2010-09-27

    IPC分类号: C07D417/00 A61K31/44

    CPC分类号: C07D513/04

    摘要: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

    摘要翻译: 本文提供了新的沉默调节蛋白的调节化合物及其使用方法。 沉默调节蛋白的调节化合物可用于增加细胞的寿命,以及治疗和/或预防各种各样的疾病和病症,包括例如与老化或紧张相关的疾病或病症,糖尿病,肥胖症,神经变性疾病, 心血管疾病,凝血障碍,炎症,癌症和/或潮红以及由线粒体活性增加所致的疾病或病症。 还提供了包含与另一种治疗剂组合的沉默调节蛋白的调节化合物的组合物。

    RESVERATROL FORMULATIONS
    7.
    发明申请
    RESVERATROL FORMULATIONS 审中-公开
    RESVERATROL公式

    公开(公告)号:US20110009496A1

    公开(公告)日:2011-01-13

    申请号:US12812172

    申请日:2009-01-07

    IPC分类号: A61K31/047 A61P39/06

    CPC分类号: A61K9/08 A61K9/107 A61K31/05

    摘要: Resveratrol can be used to treat or inhibit the onset of many diseases that are related to the aging process, but large doses are required. The present invention provides concentrated liquid formulations of resveratrol, typically having a resveratrol concentration of at least 10% by weight. These formulations improve patient compliance because the patient need not consume such a large volume of a resveratrol formulation.

    摘要翻译: 白藜芦醇可用于治疗或抑制与衰老过程相关的许多疾病的发病,但需要大剂量。 本发明提供白藜芦醇的浓缩液体制剂,其通常具有至少10重量%的白藜芦醇浓度。 这些制剂改善了患者的依从性,因为患者不需要消耗如此大量的白藜芦醇制剂。